Brintellix

(Vortioxetine)

ApprovedSmall molecule

Vortioxetine is used to treat depression by helping to restore the balance of certain chemicals in the brain that affect mood and emotion.[2] Brintellix is currently approved and in use across 24 indications[4].[1]

Brintellix is one of 576 small molecule programs targeting Frontotemporal Dementia. It is currently in Approved.

Indications

Total Trials

Active Trials

575

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Frontotemporal DementiaActive, not recruiting

Depressive DisorderApproved

Psychiatric DisorderActive, not recruiting

Eating DisorderActive, not recruiting

Mood DisorderApproved

Cognitive ImpairmentApproved

Attention Deficit Hyperactivity DisorderApproved

Parkinson DiseaseActive, not recruiting

Brain InjuryActive, not recruiting

Panic DisorderActive, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Depressive DisorderApproved

Approved

Psychiatric DisorderPhase 2/Phase 3

Active, not recruiting

Eating DisorderPhase 2

Active, not recruiting

Mood DisorderApproved

Approved

Cognitive ImpairmentApproved

Approved

Attention Deficit Hyperactivity DisorderApproved

Approved

Parkinson DiseaseApproved

Active, not recruiting

Brain InjuryPhase 3

Active, not recruiting

Panic DisorderApproved

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Brintellix

Takeda

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Aldactone

Pfizer

Preclinical

1 7

Nexavar

Bayer

Preclinical

1 8

Stivarga

Bayer

Preclinical

1 9

Singulair

AstraZeneca

Preclinical

1 10

Aimovig

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Parkinson Disease

NCT06805266

Q3 2027

Phase 1/2Recruiting

Adolescent

NCT05814640

Q2 2029

Phase 2Recruiting

Glioblastoma

NCT07284628

Q3 2029

Phase 2Recruiting

Frontotemporal Dementia

NCT06604520

Phase 3Recruiting

Major Depressive Disorder

NCT07204314

Clinical

Trials by Indication[1]

Major Depressive Disorder33 trials

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT01163266·462 enrolled

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 2/3·NCT01255787·600 enrolled

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00707980·836 enrolled

Show 30 more trials

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT01179516·469 enrolled

The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Completed·RRush University Medical Center·Phase 4·NCT02749721·31 enrolled

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Completed· Takeda logo

Takeda·Phase 4·NCT02371980·1,106 enrolled

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Withdrawn·TTodd Doyle·Phase 4·NCT03580967

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00694304·535 enrolled

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Recruiting· Takeda logo

Takeda·Phase 3·NCT07204314·180 enrolled

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01323478·71 enrolled

Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01422213·598 enrolled

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT02279966·152 enrolled

Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT00839423·426 enrolled

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01571453·437 enrolled

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT00761306·74 enrolled

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01140906·607 enrolled

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 2·NCT01564862·602 enrolled

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00811252·453 enrolled

Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00635219·766 enrolled

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT02919501·55 enrolled

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT01153009·614 enrolled

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Withdrawn·TThomas Jefferson University·Phase 1·NCT02454426

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 4·NCT02972632·123 enrolled

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT03108625·94 enrolled

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT02389816·493 enrolled

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00672620·611 enrolled

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

Unknown status·TThe Medical Research Network·Phase 4·NCT02294305·40 enrolled

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT01355081·366 enrolled

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Completed· Takeda logo

Takeda·Phase 3·NCT01364649·447 enrolled

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Withdrawn· AbbVie logo

AbbVie·Phase 3·NCT03855865

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Terminated· Lundbeck logo

Lundbeck·Phase 3·NCT02871297·662 enrolled

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00672958·600 enrolled

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00735709·560 enrolled

Depression7 trials

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Completed· Takeda logo

Takeda··NCT05932407·147,777 enrolled

Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT04288895·400 enrolled

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT04448431·605 enrolled

Show 4 more trials

Study With Vortioxetine on Emotional Functioning in Patients With Depression

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT03835715·150 enrolled

Vortioxetine for Menopausal Depression

Completed·MMassachusetts General Hospital·Phase 4·NCT02234362·47 enrolled

Vortioxetine to Prevent Return of Symptoms in Children With Depression

Terminated· Lundbeck logo

Lundbeck·Phase 3·NCT05014919·35 enrolled

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

Recruiting·MMayo Clinic·Approved·NCT07266545·120 enrolled

Generalized Anxiety Disorder4 trials

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Completed· Takeda logo

Takeda·Phase 3·NCT00744627·301 enrolled

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00731120·457 enrolled

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00734071·304 enrolled

Show 1 more trial

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Completed· Takeda logo

Takeda·Phase 3·NCT00730691·781 enrolled

Schizophrenia3 trials

Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia

Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2/3·NCT04895488·37 enrolled

Adjunctive Vortioxetine in Schizophrenia

Unknown status·NNorthwell Health·Phase 4·NCT02357797·88 enrolled

Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia

Unknown status·AAlen Greš·Phase 1·NCT04456777·120 enrolled

Anxiety Disorder2 trials

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT01491035·48 enrolled

Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT04220996·100 enrolled

38 more indications

Bipolar Depression2 trials

Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression

Unknown status·SSeoul National University Hospital·Phase 2·NCT03598868·100 enrolled

Vortioxetine Adjunctive Treatment in Bipolar Depression

Completed·FFirst Affiliated Hospital of Zhejiang University·Phase 4·NCT05481957·131 enrolled

Cognition2 trials

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

Completed· Lundbeck logo

Lundbeck·Phase 1·NCT01607125·96 enrolled

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

Withdrawn·UUniversity of Miami·Phase 4·NCT02637466

Elective1 trial

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 4·NCT03779789·362 enrolled

Observational Study1 trial

Vortioxetine for Cancer Patients With Depression: An Observational Study

Unknown status·UUniversity of Malaya··NCT04253678·140 enrolled

Concentration1 trial

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Completed· Takeda logo

Takeda·Phase 1·NCT01299805·17 enrolled

COVID-191 trial

Vortioxetine for Post-COVID-19 Condition

Completed·BBrain and Cognition Discovery Foundation·Phase 2·NCT05047952·149 enrolled

MDD1 trial

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT02332954·226 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT04446039·370,212 enrolled

Adolescent1 trial

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 1/2·NCT05814640·520 enrolled

MPR1 trial

Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities

Unknown status·SScotmann Pharmaceuticals·Phase 3·NCT05104918·500 enrolled

Frontotemporal Dementia1 trial

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

Recruiting·JJohns Hopkins University·Phase 2·NCT06604520·50 enrolled

Hoarding Disorder1 trial

Vortioxetine for the Treatment of Hoarding Disorder

Withdrawn·NNoam Soreni·Phase 3·NCT04035850

Parkinson disease1 trial

Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

Not yet recruiting·MMarianna Amboni·Phase 4·NCT06805266·40 enrolled

Cognitive Decline1 trial

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

Completed·WWashington University School of Medicine·Phase 4·NCT03272711·129 enrolled

Major Depression1 trial

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01488071·495 enrolled

Electroencephalography1 trial

Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

Completed· Lundbeck logo

Lundbeck·Phase 1·NCT02072278·32 enrolled

Intravenous1 trial

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT03766867·80 enrolled

Major Depressive Episode1 trial

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT00596817·639 enrolled

Head and Neck Cancers1 trial

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT04818099·208 enrolled

Adult1 trial

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Completed· Lundbeck logo

Lundbeck·Phase 2·NCT02327013·227 enrolled

Dementia1 trial

Vortioxetine in Patients With Depression and Early Dementia

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT04294654·82 enrolled

Psychiatric Disorder1 trial

Substance Misuse To Psychiatric Disorders for Cannabis

Completed·TThe University of Hong Kong·Phase 2/3·NCT03485274·37 enrolled

Sexual Function1 trial

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Completed· Takeda logo

Takeda·Phase 4·NCT02932904·361 enrolled

Effectiveness1 trial

Real-life Effectiveness of Vortioxetine in Depression

Completed· Lundbeck logo

Lundbeck··NCT03555136·992 enrolled

Cognitive Function1 trial

Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

Recruiting·WWashington University School of Medicine·Phase 2·NCT07000734·20 enrolled

Brain Injury1 trial

Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)

Withdrawn·JJohns Hopkins University·Phase 3·NCT02845349

Cognitive Dysfunction1 trial

Cognitive Dysfunction in MDD Patients

Unknown status·OOleg Levada·Phase 4·NCT03187093·150 enrolled

Safety and Efficacy1 trial

Tolerability, Safety and Efficacy of Vortioxetine

Unknown status·IIRCCS San Raffaele Roma·Phase 4·NCT04301492·20 enrolled

Relapse1 trial

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT03830827·220 enrolled

Post-Traumatic Stress Disorder1 trial

Vortioxetine for Posttraumatic Stress Disorder

Completed·UUniversity of Miami·Phase 4·NCT02637895·41 enrolled

AIN1 trial

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

Terminated·MMassachusetts General Hospital·Phase 4·NCT02969876·2 enrolled

Alcohol Use1 trial

Vortioxetine for Treatment of Depressive Mood and Alcohol Use

Unknown status·HHanyang University Seoul Hospital·Phase 2·NCT04498897·128 enrolled

Panic Disorder1 trial

A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder

Completed·SSiyan Clinical Corporation·Phase 4·NCT02395510·27 enrolled

PET1 trial

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Unknown status·—··NCT05840861·59 enrolled

Eating Disorder1 trial

Vortioxetine for Binge Eating Disorder

Completed·UUniversity of Chicago·Phase 2·NCT02528409·80 enrolled

Hepatic Impairment1 trial

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Completed· Takeda logo

Takeda·Phase 1·NCT02170220·12 enrolled

Glioblastoma1 trial

A Phase II Drug Repurposing Trial of Vortioxetine for the Treatment of Patients With Newly Diagnosed Glioblastoma

Recruiting·UUniversity of Zurich·Phase 2·NCT07284628·78 enrolled

Unspecified4 trials

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Completed· Takeda logo

Takeda·Phase 1·NCT03437564·28 enrolled

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

Completed· Takeda logo

Takeda·Phase 3·NCT01152996·1,075 enrolled

Vortioxetine vs Sertraline in Mexicans

Completed·—·Phase 4·NCT03978286·21 enrolled

Show 1 more trial

THINC-it Vortioxetine - Sensitivity to Change

Completed·BBrain and Cognition Discovery Foundation·Phase 2/3·NCT03053362·158 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 30, 2013

TRINTELLIX

NDA NDA204447

Sources

References

[1]
ClinicalTrials.gov — 92 trial records for Vortioxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Brintellix drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Vortioxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Vortioxetine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204447). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Brintellix. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin 1a (5-Ht1a) Receptor Agonist; Serotonin Transporter Inhibitor; Serotonin 3a (5-Ht3a) Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Takeda

Patent Landscape[6]

Patent Cliff

Dec 17, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7144884Jun 17, 2026

7144884*PEDDec 17, 2026

9125908Jun 15, 2027

9125909Jun 15, 2027

9125910Jun 15, 2027

15 more patents

9227946Jun 15, 2027

8969355Jun 15, 2027

11458134Jun 15, 2027

9861630Jun 15, 2027

11458134*PEDDec 15, 2027

9125908*PEDDec 15, 2027

9125909*PEDDec 15, 2027

9125910*PEDDec 15, 2027

9861630*PEDDec 15, 2027

8969355*PEDDec 15, 2027

9227946*PEDDec 15, 2027

8722684Jun 30, 2031

8722684*PEDDec 30, 2031

9278096Mar 21, 2032

9278096*PEDSep 21, 2032

Brintellix

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q2 2029

Q3 2029

Trials by Indication[1]

Major Depressive Disorder33 trials

Depression7 trials

Generalized Anxiety Disorder4 trials

Schizophrenia3 trials

Anxiety Disorder2 trials

Bipolar Depression2 trials

Cognition2 trials

Elective1 trial

Observational Study1 trial

Concentration1 trial

COVID-191 trial

MDD1 trial

Cohort Study1 trial

Adolescent1 trial

MPR1 trial

Frontotemporal Dementia1 trial

Hoarding Disorder1 trial

Parkinson disease1 trial

Cognitive Decline1 trial

Major Depression1 trial

Electroencephalography1 trial

Intravenous1 trial

Major Depressive Episode1 trial

Head and Neck Cancers1 trial

Adult1 trial

Dementia1 trial

Psychiatric Disorder1 trial

Sexual Function1 trial

Effectiveness1 trial

Cognitive Function1 trial

Brain Injury1 trial

Cognitive Dysfunction1 trial

Safety and Efficacy1 trial

Relapse1 trial

Post-Traumatic Stress Disorder1 trial

AIN1 trial

Alcohol Use1 trial

Panic Disorder1 trial

PET1 trial

Eating Disorder1 trial

Hepatic Impairment1 trial

Glioblastoma1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News